Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Curcumin, BioPerine Combo Offers Benefits for Metabolic Syndrome

Article-Curcumin, BioPerine Combo Offers Benefits for Metabolic Syndrome

<p>Sabinsa&#8217;s Curcumin C3 Complex&#174; and BioPerine&#174; combination may provide beneficial effects for patients with metabolic syndrome.</p>

EAST WINDSOR, N.J.—Sabinsa’s Curcumin C3 Complex® and BioPerine® combination may provide beneficial effects for patients with metabolic syndrome. (Complementary Therapies in Medicine. 2014; 22(5): 851-857)   

A randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted with 117 patients for eight weeks. Patients received either Curcumin C3 Complex plus BioPerine combination or matched placebo capsules twice daily for eight weeks. Complete lipid profiles, including LDL-C, non-HDL-C, total cholesterol, triglyceride and Lp(a), were determined at the baseline and at end of the trial. 

The study results showed significantly greater effect of curcuminoids in reducing the serum concentrations of LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a) in comparison to the placebo group. Serum HDL-C concentration was elevated significantly in the curcuminoids group. Serum sdLDL levels were comparable in both groups at baseline and at the end of the trial. Overall effects of curcuminoids on triglycerides, non-HDL-C, total cholesterol and Lp(a) remained significant after adjustment for baseline BMI. The Curcumin C3 Complex plus BioPerine combination was well tolerated in patients with metabolic syndrome. 

This study is the first trial investigating the efficacy and safety of adjunctive therapy with a curcuminoids-piperine combination in patients with metabolic syndrome, receiving standard treatment. The results of the trial supported the effectiveness of the adjunctive therapy with significant decrease in serum concentration LDL-C, non-HDL-C, total cholesterol, triglyceride, Lp(a) and elevation in serum concentration of HDL-C in patients in comparison to the standard therapy alone. The present study also encouraged the efficacy of use of co-administering BioPerine as a bioavailability enhancer.  

“This research indicates additional benefits of curcumin beyond inflammation, giving increased value to C3 Complex as the body of science grows," said Shaheen Majeed, Sabinsa’s marketing director.  “And once again, the C3 Complex and BioPerine combination has been shown to be a safe and effective supplement blend that can help keep people healthy."  

Sabinsa’s Curcumin C3 Complex has been subject of more than 72 research papers, including 34 clinical studies published in peer reviewed journals. The combination of Curcumin C3 Complex and BioPerine has been studied in several independent clinical trials, including one published by Tufts University (validating its safety and quality of ingredients) and another on osteoarthritis from University of Medical Sciences, Mashhad, Iran. 

Earlier this year, Sabinsa received four new international patents for several ingredients and proprietary blends.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.